New KCC City Clinic in New Baneshwor is now open.
  1. Home
  2. Treatments
  3. Immunotherapy
Nivolumab and pembrolizumab

Immunotherapy in Nepal

At Kathmandu Cancer Center, at the standard dose or with flexible dosing.

For patients who could not otherwise receive it, flexible dosing lowers the drug cost by about 80 to 90%, backed by published research. Send us your reports and we will tell you in writing what is possible for your cancer.

इम्युनोथेरापीबारे नेपालीमा पढ्नुहोस्

A KCC nurse preparing an immunotherapy infusion inside the chemotherapy preparation cabinet at Kathmandu Cancer Center
Results from our own patientsPublished in Cancer Reports, 2026
  • Since 2022Immunotherapy available in Kathmandu
  • 31 patientsOur own results, published in 2026
  • 80 to 90%Lower drug cost with flexible dosing
  • Tumour boardReviews every complex case

Is immunotherapy available in Nepal?

Yes. Immunotherapy with nivolumab and pembrolizumab is available at Kathmandu Cancer Center. It is given as a drip into a vein. Patients can receive the standard dose, or flexible dosing if cost would otherwise stop them from having treatment. Your oncologist chooses with you after looking at your cancer type, biomarker tests and general health.

Drugs
Nivolumab, pembrolizumab
Where
Tathali, Bhaktapur, and City Clinic, New Baneshwor
Dose options
Standard dose or flexible dosing
First step
WhatsApp your reports to 9818-226237
Last reviewed
October 2026

Which cancers can immunotherapy help?

Immunotherapy helps some cancers and not others, and often only in certain settings. Find your cancer to see who it is for, which tests come first, and what KCC offers.

  • Lung cancer

    Used in many non-small cell lung cancers, on its own or with chemotherapy, and after chemoradiation in some stage 3 cases. Also added to chemotherapy in small cell lung cancer.

    Treatment for lung cancer at KCC
  • Breast cancer (triple-negative)

    Helps some patients with triple-negative breast cancer, given with chemotherapy before and after surgery, or when the cancer has spread. It is not a standard treatment for most other types of breast cancer.

    Treatment for breast cancer at KCC
  • Head and neck cancer

    Mouth, throat and larynx. Used mainly when the cancer has come back or spread, and in selected earlier cases. Much of the flexible dosing research is in this cancer.

    Treatment for head and neck cancer at KCC
  • Cervical cancer

    Used with chemotherapy when the cancer has come back or spread, and in some high-risk cases together with chemoradiation.

    Treatment for cervical cancer at KCC
  • Oesophageal cancer (food pipe)

    Used with chemotherapy as first treatment for advanced squamous cell cancer, and in some patients after chemoradiation and surgery.

    Ask about oesophageal cancer on WhatsApp
  • Stomach cancer

    Added to chemotherapy for advanced stomach and gastro-oesophageal junction cancer.

    Treatment for stomach cancer at KCC
  • Liver cancer

    Used for advanced liver cancer, usually combined with bevacizumab or another immunotherapy drug. It depends on how well the liver is working.

    Treatment for liver cancer at KCC
  • Bowel cancer (colon and rectum)

    Works very well in the small group whose tumours are MSI-high or dMMR. It does not help most other bowel cancers, so testing comes first.

    Treatment for colon or rectal cancer at KCC
  • Gallbladder and bile duct cancer

    Used with chemotherapy for advanced disease.

    Ask about gallbladder or bile duct cancer on WhatsApp
  • Other cancers

    Hodgkin lymphoma, melanoma and other skin cancers, bladder cancer, cancer of the womb lining, and nasopharyngeal cancer. Send your reports and a doctor will tell you whether immunotherapy is an option.

    Ask about my type of cancer on WhatsApp

The tests that come first for each cancer are listed in the next section.

Tests that decide whether immunotherapy can help

Immunotherapy does not work for every cancer, so the tests come before the treatment. They are done on tissue from your biopsy and help your doctors judge whether immunotherapy is likely to work for you.

PD-L1
Shows how much of the "hiding" protein the cancer makes. A higher level makes a good response more likely in several cancers, including some lung and head and neck cancers.
MSI / dMMR
Checks whether the cancer cells are unable to repair their own genetic errors. Tumours with this change often respond very well, whichever organ they started in. It matters most in bowel, stomach and womb cancers.
TMB
Counts how many genetic changes the cancer has. More changes give the immune system more to recognise.
EGFR and ALK
Checked first in lung cancer. If one of these changes is present, tablets that target it usually come before immunotherapy.
HER2
Checked in stomach and breast cancer. It decides whether a targeted drug is added.

Which tests come first

CancerTests that usually come first
LungPD-L1, EGFR, ALK
Oesophagus, stomach and gastro-oesophageal junctionPD-L1 (CPS), HER2, MSI / dMMR
Bowel (colon and rectum)MSI / dMMR
Liver, gallbladder and bile ductDiagnosis confirmed, and how well the liver is working
Head and neckPD-L1 (CPS)
CervixPD-L1 (CPS)
Breast (triple-negative)ER, PR and HER2 to confirm the type, and PD-L1 (CPS)
Lymphoma and skin cancerDiagnosis confirmed on biopsy

Your doctors may add other tests for your case.

Need a biopsy first? Biopsy and pathology are done at KCC. See biopsy at KCC.

Biopsy done elsewhere? Bring the paraffin block or unstained slides. We can usually run these tests on the same sample, so a new biopsy is usually not needed. Or send your biopsy report on WhatsApp and we will tell you which tests are still needed.

Two ways to receive immunotherapy at KCC

Many families come to us having been told that immunotherapy is out of their reach. That is why we offer two options.

Standard dose

The dose set out in international guidelines. It is the right choice for patients who can access it and whose doctors recommend it.

Flexible dosing

A smaller amount of nivolumab per treatment, based on published studies that include a randomised trial of more than 500 patients. The drug cost is about 80 to 90% lower. We offer it so that cost does not decide who gets immunotherapy.

How we decide. Your oncologist and our tumour board go through your cancer type, how far it has spread, your general health and what your family can manage. They explain both options and you decide together.

Why smaller doses were tested. Laboratory studies show that nivolumab can block its target in the body at much lower amounts than the standard dose. That is why researchers asked whether a smaller dose could work as well.

What is known and what is not. No study has compared flexible dosing directly with the full dose, so we cannot tell you the two give identical results. What studies show is that flexible dosing works better than chemotherapy for the cancers tested. Your doctor will go through this with you before treatment starts.

What our own patients' results show

Our doctors reviewed the records of 31 patients with advanced cancer who received flexible dosing of nivolumab at KCC. The results were published in the journal Cancer Reports in October 2026. To our knowledge, it is the first immunotherapy study from Nepal published in a PubMed-indexed journal.

These patients had cancers of the digestive tract, lung, head and neck, the female reproductive organs, skin, and Hodgkin lymphoma.

16 of 31The cancer shrank or disappeared on scans
4 of 31No cancer was visible on scans after treatment
About 15 monthsHalf of the patients were still alive beyond this point (14.8 months)
5 of 31Had moderate or serious side effects (joint pain, loose motions, fluid around the heart). None had the most severe kind.

What this study cannot tell you

It is a small group from one hospital, looked at after treatment, with no comparison group. It does not promise the same result for your cancer. It does show that flexible dosing works in real patients in Nepal, not only in trials abroad.

Source: Pandit S, Sapkota S, Adhikari A, et al. Cancer Reports 2026;9(10):e70713. DOI 10.1002/cnr2.70713

Read the paperPubMed

The research behind flexible dosing

The DELII trial, run at Tata Memorial Hospital in Mumbai and published in the Journal of Clinical Oncology in 2026, gave more than 500 patients with advanced cancers about one twelfth of the standard nivolumab dose and compared them with patients on chemotherapy. Patients on nivolumab lived longer (median survival 5.88 months against 4.7 months, and 27.3% alive after one year against 16.9%) and had fewer serious side effects.

The gain is modest, and it is not a cure. The trial did not compare against full-dose nivolumab. KCC began offering flexible dosing in 2022, before this trial was published.

DELII paperPubMedOur blog post: Immunotherapy in Nepal, Options for Every Family

What does immunotherapy cost in Nepal?

Until recently, only a small minority of patients in Nepal could afford immunotherapy. Flexible dosing is how we are changing that.

The cost depends on the drug, the dose and how many treatments you need, and drug prices change, so we do not print a figure on this page. In general, flexible dosing lowers the drug cost by about 80 to 90% compared with the standard dose.

Send your reports on WhatsApp and we will send you a written estimate for your case, usually within a day. You decide after that, not before. The drug estimate does not include consultation, infusion or lab charges.

How to get your written opinion

  1. Send your reports on WhatsApp: diagnosis, biopsy report, scans and any biomarker results you already have.
  2. A KCC doctor reads them, and our tumour board reviews complex cases.
  3. You receive a written opinion and an estimate for your case, usually within a day.

Drugs available at KCC

DrugUsed for
Nivolumab
also sold as Opdivo
Head and neck cancer, non-small cell lung cancer, oesophageal cancer, bladder cancer, stomach and gastro-oesophageal junction cancer, MSI-high tumours of any organ
Pembrolizumab
also sold as Keytruda
Lung cancer with PD-L1 50% or higher (first line), head and neck cancer, cervical cancer, triple-negative breast cancer, biliary tract cancer, MSI-high or dMMR tumours of any organ

Durvalumab, atezolizumab and ipilimumab: we confirm availability for your case before you travel. Trastuzumab, bevacizumab and rituximab are targeted therapies and work differently from immunotherapy. See our targeted therapy page.

How immunotherapy works and what treatment is like

How it works

Your immune system can recognise cancer cells. Some cancers survive by making a protein called PD-L1, which switches off the T-cells that would attack them. Nivolumab and pembrolizumab block that signal, so your T-cells can see the cancer again. The drug does not kill cancer cells itself. It gets your own defences working.

The infusion

The drug goes into a vein as a drip. Each infusion takes 30 to 60 minutes. Between treatments most patients carry on with daily life and work. We check your blood before each treatment. Your doctor decides how many treatments you need and for how long, and writes it in your treatment plan.

Side effects

Immunotherapy usually does not cause the hair loss and severe nausea that chemotherapy can. It has its own side effects, because it switches the immune system on. Skin rash or itching, joint pain, loose motions and tiredness are the common ones. Less often, the immune system inflames the lungs, liver, kidneys or hormone glands. These can be serious but are treatable when found early, which is why we ask you to call early.

Call us the same day if you have

  • Fever
  • Loose motions that do not settle
  • A new cough or breathlessness
  • A severe rash or blisters
  • Yellow eyes or skin
  • Unusual weakness

Phone 01-5091629. Tell any other doctor or hospital you visit that you are on immunotherapy.

Dr. Simit Sapkota explains immunotherapy

Where you can be treated

Kathmandu Cancer Center, Tathali, Bhaktapur

Main hospital. Sunday to Friday, 9 am to 5 pm.

KCC City Clinic, New Baneshwor, Kathmandu

Immunotherapy infusions in central Kathmandu, so you do not have to go to Bhaktapur for every treatment.

Started treatment elsewhere, or deciding where to go?

  • Already on immunotherapy in India or another country. WhatsApp your treatment summary and recent reports. We can usually confirm drug availability within a few days and continue your plan without starting over. Transferring treatment from India
  • Still deciding where to be treated. The same drugs and the same international guidelines (NCCN, ESMO) are used here. You can send your reports for a second opinion before you travel anywhere. Second opinion
  • Why some families prefer treatment at home. You stay near your family, and nobody has to leave work and home for months. Why treatment in Nepal

Other immune-based treatment

CAR-T cell therapy is a different kind of immunotherapy for some blood cancers. A patient's own T-cells are taken out, changed in a laboratory and given back. CAR-T therapy at KCC

Frequently asked questions

Is immunotherapy available in Nepal?
Yes. Nivolumab and pembrolizumab are available at Kathmandu Cancer Center in Tathali, Bhaktapur, and infusions are also given at our City Clinic in New Baneshwor. We have offered immunotherapy since 2022.
Do I need to go to India for immunotherapy?
No. The same drugs and the same international treatment guidelines are used at KCC. If you have already started treatment in India, we can usually continue it here. If you are still deciding, you can send your reports for a second opinion first.
What is flexible dosing?
Flexible dosing means giving a smaller amount of nivolumab per treatment than the standard dose. It is based on published studies, including the DELII trial and our own patients' results. It lowers the drug cost by about 80 to 90%, so that patients who could not otherwise afford immunotherapy can have it. The oncologist and tumour board choose the dose for each patient.
Is flexible dosing as effective as the standard dose?
No study has compared the two directly, so nobody can say for sure that they give identical results. The DELII trial showed that flexible dosing worked better than chemotherapy, with fewer serious side effects. Our own results in 31 patients were also encouraging, though that study was small. Your doctor will explain what is known for your cancer.
Can I have the standard dose at KCC?
Yes. Standard-dose immunotherapy is available. Which option suits you depends on your cancer, your health and your situation, and you decide together with your doctor.
How much does immunotherapy cost in Nepal?
It depends on the drug, the dose and how many treatments you need, and drug prices change, so we do not print a figure. Flexible dosing lowers the drug cost by about 80 to 90% compared with the standard dose. Send your reports to 9818-226237 on WhatsApp and we will send a written estimate for your case, usually within a day. The estimate covers the drug. Consultation, infusion and lab charges are separate.
Will immunotherapy work for my cancer?
It depends. Immunotherapy helps in some cancers and not in others. Biomarker tests such as PD-L1 and MSI help predict who is more likely to respond. Our tumour board looks at your cancer type, stage, test results and general health before recommending it. We can usually test the biopsy sample you already have.
What is the difference between immunotherapy and chemotherapy?
Chemotherapy kills fast-dividing cells, including cancer cells and some healthy ones such as hair roots and the lining of the gut. Immunotherapy does not kill cancer cells directly. It helps your own immune system recognise and attack the cancer. The side effects differ too. They come from an overactive immune system, such as rash, joint pain or loose motions.
What side effects should I watch for?
Skin rash, itching, joint pain, loose motions and tiredness are the most common. Call us the same day if you have fever, loose motions that do not settle, a new cough or breathlessness, a severe rash, yellow eyes or skin, or unusual weakness. Phone 01-5091629.
Can I continue immunotherapy that I started in India or another country?
Yes. Send your treatment summary, the drug name and dose, recent blood reports and the date of your last treatment on WhatsApp (9818-226237). We can usually confirm drug availability within a few days and continue your plan.

Send your reports. We will reply in writing.

WhatsApp the diagnosis, biopsy report and any scans or biomarker results you have to 9818-226237. A doctor reads them, and you usually hear back within a day. You decide after that, not before.

Related pages

Reviewed by Dr. Subhas Pandit and Dr. Simit Sapkota. Last reviewed October 2026. This page is general information and does not replace advice from your own doctor.

  1. Pandit S, Sapkota S, Adhikari A, et al. Low-Dose Nivolumab in Various Cancers: A Real-World Exploratory Analysis in Resource-Constrained Settings. Cancer Reports 2026;9(10):e70713. DOI 10.1002/cnr2.70713
  2. Noronha V, et al. Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). J Clin Oncol 2026. DOI 10.1200/JCO-25-01546
  3. Patil V, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. J Clin Oncol 2023. DOI 10.1200/JCO.22.01015